Genetic and biochemical modulation of 5-fluorouracil through the overexpression of thymidine kinase: An in-vitro study

Anti-Cancer Drugs

Volumn 17, Issue 4, 2006, Pages 463-470

  Fanciullino, Raphaelle ^a   Evrard, Alexandre ^b   Cuq, Pierre ^b   Giacometti, Sarah ^a   Peillard, Laurent ^a   Mercier, Cédric ^a   Aubert, Claude ^a   Milano, Gérard ^c   Ciccolini, Joseph ^a,d  

^a School of Pharmacy   (France)

^b Department of Pharmaceutical Chemistry   (France)

^c CENTRE ANTOINE LACASSAGNE   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

Author keywords

5 fluorouracil; HT29; Metabolism; Resistance; Thymidine kinase; Thymidylate synthase

Indexed keywords

COMPLEMENTARY DNA; DNA; FLOXURIDINE DERIVATIVE; FLUORODEOXYURIDINE MONOPHOSPHATE; FLUOROURACIL; THYMIDINE KINASE; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG; VIRUS VECTOR;

ARTICLE; CANCER CELL; CELL PROLIFERATION; COLON; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ACTIVATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG SCREENING; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECTUM; SCREENING;

CELL LINE, TUMOR; DNA, COMPLEMENTARY; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VECTORS; HUMANS; THYMIDINE KINASE; TRANSFECTION;

EID: 33748193780     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000198914.83195.61     Document Type: Article

References (39)

1. Wang W, Cassidy J, O'Brien V, Ryan KM, Collie-Duguid E. Mechanistic and predictive profiling of 5-Fluorouracil resistance in human cancer cells. Cancer Res 2004; 64:8167-8176.
2. Laskin JD, Evans RM, Slocum HK, Burke D, Hakala MT. Basis for natural variation in sensitivity to 5-fluorouracil in mouse and human cells in culture. Cancer Res 1979; 39:383-390.
3. Berger SH, Hakala MT. Relationship of dUMP and free FdUMP pools to inhibition of thymidylate synthase by 5-fluorouracil. Mol Pharmacol 1984; 25:303-309.
4. Peters GJ, van Groeningen CJ, Laurensse EJ, Pinedo HM. A comparison of 5-fluorouracil metabolism in human colorectal cancer and colon mucosa. Cancer 1991; 8:1903-1909.
5. Cao D, Pizzorno G. Uridine phosphorylase: an important enzyme in pyrimidine metabolism and fluoropyrimidine activation. Drugs Today (Barc) 2004; 40:431-443.
6. Evrard A, Cuq P, Ciccolini J, Vian L, Cano JP. Increased cytotoxicity and bystander effect of 5-fluorouracil and 5-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase. Br J Cancer 1999; 80:1726-1733.
7. Ciccolini J, Peillard L, Aubert C, Formento P, Milano G, Catalin J. Monitoring of the intracellular activation of 5-fluorouracil to deoxyribonucleotides in HT29 human colon cell line: application to modulation of metabolism and cytotoxicity study. Fundam Clin Pharmacol 2000; 14:147-154.
8. Ciccolini J, Peillard L, Evrard A, Cuq P, Aubert C, Pelegrin A, et al. Enhanced antitumor activity of 5-fluorouracil in combination with 2′-deoxyinosine in human colorectal cell lines and human colon tumor xenografts. Clin Cancer Res 2000; 6:1529-1535.
9. Ciccolini J, Cuq P, Evrard A, Giacometti S, Pelegrin A, Aubert C, et al. Combination of thymidine phosphorylase gene transfer and deoxyinosine treatment greatly enhances 5-fluorouracil antitumor activity in vitro and in vivo. Mol Cancer Ther 2001; 1:133-139.
10. Ciccolini J, Fina F, Bezulier K, Giacometti S, Roussel M, Evrard A, et al. Transmission of apoptosis in human colorectal tumor cells exposed to capecitabine, Xeloda, is mediated via Fas. Mol Cancer Ther 2002; 1:923-927.
11. Broet P, Romain S, Daver A, Ricolleau G, Quillien V, Rallet A, et al. Thymidine kinase as a proliferative marker: clinical relevance in 1,692 primary breast cancer patients. J Clin Oncol 2001; 19:2778-2787.
12. Taylor AT, Stafford MA, Jones OW. Properties of thymidine kinase partially purified from human fetal and adult tissue. J Biol Chem 1972; 247:1930-1935.
13. Fujiwaki R, Hata K, Nakayama K, Moriyama M, Iwanari O, Katabuchi H, et al. Thymidine kinase in epithelial ovarian cancer: relationship with the other pyrimidine pathway enzymes. Int J Cancer 2002; 99:328-335.
14. Myers CE, Young RC, Johns DG, Chabner BA. Assay of 5′- fluorodeoxyuridine 50-monophosphate deoxyuridine 5-monophosphate pools following 5-fluorouracil. Cancer Res 1974; 34:2682-2688.
15. 1-S-regulated transcription. J Biol Chem 1992; 267:2723-2727.
16. Mikulits W, Hengstschlager M, Sauer T, Wintersberger E, Mullner EW. Overexpression of thymidine kinase mRNA eliminates cell cycle regulation of thymidine kinase enzyme activity. J Biol Chem 1996; 271:853-860.
17. Inaba M, Naoe Y, Mitsuhashi J. Mechanisms for 5-fluorouracil resistance in human colon cancer DLD-1 cells. Biol Pharm Bull 1998; 21:569-573.
18. Zhang ZG, Harstrick A, Rustum YM. Mechanisms of resistance to fluoropyrimidines. Semin Oncol 1992; 19 (Suppl):S4-S9.
19. Zhang ZG, Malmberg M, Yin MB, Slocum HK, Rustum YM. Isolation and characterization of a human ileocecal carcinoma cell line (HCT-8) subclone resistant to fluorodeoxyuridine. Biochem Pharmacol 1993; 45:1157-1164.
20. Look KY, Moore DH, Sutton GP, Prajda N, Abonyi M, Weber G. Increased thymidine kinase and thymidylate synthase activities in human epithelial ovarian carcinoma. Anticancer Res 1997; 17:2353-2356.
21. Findenig G, Mader RM, Fritzer-Szekeres M, Steger GG, Jaeger W, Szekeres T. Modulation of 5-fluorouracil resistance in human colon tumor cell lines by azidothymidine. Oncol Res 1996; 8:189-196.
22. Van Dillen IJ, Mulder NH, Meijer C, Dam WA, Kamstra E, De Vries L, et al. Antagonism of HSV-tk transfection and ganciclovir treatment on chemotherapeutic drug sensitivity. J Chemother 2005; 17:289-296.
23. Milanesi G, Barbanti-Brodano G, Negrini M, Lee D, Corallini A, Caputo A, et al. BK virus-plasmid expression vector that persists episomally in human cells and shuttles into Escherichia coli. Mol Cell Biol 1984; 4:1551-1560.
24. Cuq P, Rouquet C, Evrard A, Ciccolini J, Vian L, Cano JP. Fluoropyrimidine sensitivity of human MCF-7 breast cancer cells stably transfected with human uridine phosphorylase. Br J Cancer 2001; 84:1677-1680.
25. Schwartz EL, Baptiste N, Megati S, Wadler S, Otter BA. 5-Ethoxy-2́-deoxyuridine, a novel substrate for thymidine phosphorylase, potentiates the antitumor activity of 5-fluorouracil when used in combination with interferon, an inducer of thymidine phosphorylase expression. Cancer Res 1995; 55:3543-3550.
26. Schwartz EL, Baptiste N, Wadler S, Makower D. Thymidine phosphorylase mediates the sensitivity of human colon carcinoma cells to 5-fluorouracil. J Biol Chem 1995; 270:19073-19077.
27. Braybrooke JP, Propper DJ, O'Byrne KJ, Koukourakis MI, Patterson AV, Houlbrook S, et al. Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alpha. Br J Cancer 2000; 83:219-224.
28. Hotchkiss KA, Ashton AW, Klein RS, Lenzi ML, Zhu GH, Schwartz EL. Mechanisms by which tumor cells and monocytes expressing the angiogenic factor thymidine phosphorylase mediate human endothelial cell migration. Cancer Res 2003; 63:527-533.
29. Ciccolini J, Evrard A, Cuq P. Thymidine phosphorylase and fluoropyrimidines efficacy: a Jekyll and Hyde story. Curr Med Chem Anticancer Agents 2004; 4:71-81.
30. Romain S, Martin PM, Klijn JG, van Putten WL, Look MP, Guirou O, et al. DNA-synthesis enzyme activity: a biological tool useful for predicting anti-metabolic drug sensitivity in breast cancer? Int J Cancer 1997; 74:156-161.
31. van der Wilt CL, Backus HH, Smid K, Comijn L, Veerman G, Wouters D, et al. Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors. Cancer Res 2001; 61:3675-3681.
32. Chung YM, Park S, Park JK, Kim Y, Kang Y, Yoo YD. Establishment and characterization of 5-fluorouracil-resistant gastric cancer cells. Cancer Lett 2000; 159:95-101.
33. Gmeiner WH, Trump E, Wei C. Enhanced DNA-directed effects of FdUMP[10] compared to 5FU. Nucleosides Nucleotides Nucleic Acids 2004; 23:401-410.
34. Leteurtre E, Gouyer V, Rousseau K, Moreau O, Barbat A, Swallow D, et al. Differential mucin expression in colon carcinoma HT-29 clones with variable resistance to 5-fluorouracil and methotrexate. Biol Cell 2004; 96:145-251.
35. Fanciullino R, Giacometti S, Aubert C, Fina F, Martin PM, Piccerelle P, et al. Development of stealth liposome formulation of 2′-deoxyinosine as 5-fluorouracil modulator: in vitro and in vivo study. Pharm Res 2005; 22:2051-2057.
36. Ackland SP, Peters GJ. Thymidine phosphorylase: its role in sensitivity and resistance to anticancer drugs. Drug Resist Updat 1999; 2:205-214.
37. Tsavaris N, Kosmas C, Polyzos A, Genatas K, Vadiaka M, Paliaros P, et al. Leucovorin + 5-fluorouracil plus dipyridamole in leucovorin + 5-fluorouracil-pretreated patients with advanced colorectal cancer: a pilot study of three different dipyridamole regimens. Tumori 2001; 87:303-307.
38. Yasuda C, Kato M, Kuroda D, Ohyanagi H. Experimental studies on potentiation of the antitumor activity of 5-fluorouracil with 3′-azido-3′-deoxythymidine for the gastric cancer cell line MKN28 in vivo. Jpn J Cancer Res 1997; 88:97-102.
39. Li YX, Coucke PA, Paschoud N, Mirimanoff RO. Cytotoxic interactions of 5-fluorouracil and nucleoside analogues in vitro. Anticancer Res 1997; 17:21-27.